Joel Dillon Crandall

Array ( [id] => 17867378 [patent_doc_number] => 20220290114 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => ANTIMICROBIAL ENDOLYSIN POLYPEPTIDES, COMPOSITIONS AND FORMULATIONS [patent_app_type] => utility [patent_app_number] => 17/427453 [patent_app_country] => US [patent_app_date] => 2020-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61908 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17427453 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16221180 [patent_doc_number] => 20200246296 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-06 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING ANXIETY-RELATED DISORDERS [patent_app_type] => utility [patent_app_number] => 16/778334 [patent_app_country] => US [patent_app_date] => 2020-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9079 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16778334 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16204885 [patent_doc_number] => 20200237875 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-30 [patent_title] => FORMULATIONS AND METHODS FOR TREATMENT OF FIBROMYALGIA AND RELATED MYOFASCIAL PAIN DISORDERS [patent_app_type] => utility [patent_app_number] => 16/777274 [patent_app_country] => US [patent_app_date] => 2020-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19896 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16777274 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17532289 [patent_doc_number] => 20220110898 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-14 [patent_title] => TREATMENT OF STK11-LOSS CANCERS [patent_app_type] => utility [patent_app_number] => 17/298251 [patent_app_country] => US [patent_app_date] => 2019-12-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11109 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17298251 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19808326 [patent_doc_number] => 12239685 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-04 [patent_title] => Composition [patent_app_type] => utility [patent_app_number] => 17/416677 [patent_app_country] => US [patent_app_date] => 2019-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9425 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17416677 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16435729 [patent_doc_number] => 20200353054 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-12 [patent_title] => USE OF AVE0010 FOR THE TREATMENT OF DIABETES MELLITUS TYPE 2 [patent_app_type] => utility [patent_app_number] => 16/713815 [patent_app_country] => US [patent_app_date] => 2019-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12141 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16713815 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19916207 [patent_doc_number] => 12291560 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-06 [patent_title] => Dimerizing agent regulated immunoreceptor complexes [patent_app_type] => utility [patent_app_number] => 17/312116 [patent_app_country] => US [patent_app_date] => 2019-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 32803 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17312116 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15738323 [patent_doc_number] => 20200108049 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-09 [patent_title] => PHARMACEUTICAL COMPOSITIONS AND METHODS [patent_app_type] => utility [patent_app_number] => 16/710043 [patent_app_country] => US [patent_app_date] => 2019-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7402 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 167 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16710043 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17059009 [patent_doc_number] => 11103591 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-31 [patent_title] => Bicyclic peptide ligands specific for MT1-MMP [patent_app_type] => utility [patent_app_number] => 16/705446 [patent_app_country] => US [patent_app_date] => 2019-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 14 [patent_no_of_words] => 19739 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16705446 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17369939 [patent_doc_number] => 20220024991 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => ENGINEERED FLAGELLIN-DERIVED COMPOSITIONS AND USES [patent_app_type] => utility [patent_app_number] => 17/299373 [patent_app_country] => US [patent_app_date] => 2019-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44617 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -50 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17299373 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17356789 [patent_doc_number] => 20220017585 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => CXCR3 LIGAND [patent_app_type] => utility [patent_app_number] => 17/299629 [patent_app_country] => US [patent_app_date] => 2019-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24595 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17299629 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17451872 [patent_doc_number] => 11266709 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-08 [patent_title] => Methods for the regulation of matrix metalloproteinase expression [patent_app_type] => utility [patent_app_number] => 16/700321 [patent_app_country] => US [patent_app_date] => 2019-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 12 [patent_no_of_words] => 13315 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16700321 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17546713 [patent_doc_number] => 20220118054 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => COMBINATION TREATMENT FOR RESISTANT HYPERTENSION [patent_app_type] => utility [patent_app_number] => 17/292083 [patent_app_country] => US [patent_app_date] => 2019-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16569 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17292083 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19677093 [patent_doc_number] => 12188947 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-07 [patent_title] => Marker for diagnosing atherosclerosis severity, and diagnostic method using same [patent_app_type] => utility [patent_app_number] => 17/293946 [patent_app_country] => US [patent_app_date] => 2019-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 28 [patent_no_of_words] => 10392 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 145 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17293946 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17369940 [patent_doc_number] => 20220024992 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => COMPOSITIONS AND METHODS COMPRISING LYSOCINS AS BIOENGINEERED ANTIMICROBIALS FOR USE IN TARGETING GRAM-NEGATIVE BACTERIA [patent_app_type] => utility [patent_app_number] => 17/289878 [patent_app_country] => US [patent_app_date] => 2019-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18522 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17289878 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15828601 [patent_doc_number] => 20200129582 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-30 [patent_title] => NOVEL PEPTIDES AND PEPTIDOMIMETICS [patent_app_type] => utility [patent_app_number] => 16/669217 [patent_app_country] => US [patent_app_date] => 2019-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39364 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16669217 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17228631 [patent_doc_number] => 20210355187 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-18 [patent_title] => GLP-2 FUSION POLYPEPTIDES AND USES FOR TREATING AND PREVENTING GASTROINTESTINAL CONDITIONS [patent_app_type] => utility [patent_app_number] => 17/288824 [patent_app_country] => US [patent_app_date] => 2019-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21131 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -81 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17288824 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17343655 [patent_doc_number] => 20220009986 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-13 [patent_title] => INTERLEUKIN-10 POLYPEPTIDE CONJUGATES, DIMERS THEREOF, AND THEIR USES [patent_app_type] => utility [patent_app_number] => 17/285896 [patent_app_country] => US [patent_app_date] => 2019-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 66487 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17285896 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15405435 [patent_doc_number] => 20200023039 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-23 [patent_title] => THYMOSIN ALPHA 1 FOR USE IN TREATMENT OF CYSTIC FIBROSIS [patent_app_type] => utility [patent_app_number] => 16/593226 [patent_app_country] => US [patent_app_date] => 2019-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7469 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16593226 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15432449 [patent_doc_number] => 20200030407 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => Stable Formulations of Linaclotide [patent_app_type] => utility [patent_app_number] => 16/583500 [patent_app_country] => US [patent_app_date] => 2019-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16083 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16583500 [rel_patent_id] =>[rel_patent_doc_number] =>)